# of Displayed Technologies: 6 / 6

Applied Category Filter (Click To Remove): Clinical Area


Categories

T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
  • College: OSU Wexner Medical Center
  • Inventors: Rubinstein, Mark
  • Licensing Officer: Willson, Christopher

Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
  • College: OSU Wexner Medical Center
  • Inventors:
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Junctional Tourniquet for Groin and Axillary Regions
TS-041808 — A tourniquet with a ratcheting lock to keep pressure on wounds in the groin and axillary regions. Hemostasis can be achieved while the patient is still in the field.
Patients with blood loss in the field need to be treated immediately to prevent ongoing blood loss, shock, and death; bleeding from extremity and junctional wounds is the leading cause of potentially preventable death from penetrating injuries. Direct manual pressure is effective for the initial c…
  • College: OSU Wexner Medical Center
  • Inventors: Nocera, Tanya; Graham, Nadi; McElroy, James
  • Licensing Officer: Taysavang, Panya

Six Degrees-of-Freedom Quality Assurance Phantom for Radiation Therapy Linear Accelerators
TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.
6DoF treatment tables allow for 2 additional degrees (pitch and roll) compared to traditional 4DoF (vertical, lateral, longitudinal, and yaw) when correcting for patient setup during image-guidance prior to treatment delivery. These tables allow for more accurate patient treatments and could poten…
  • College: OSU Wexner Medical Center
  • Inventors: Woods, Kyle; Ayan, Ahmet; Gupta, Nilendu; Woollard, Jeffrey
  • Licensing Officer: Schworer, Adam

Loading icon